TITLE

The Pharmaceutical Medicine Year that Was

AUTHOR(S)
Fox, Anthony W.
PUB. DATE
December 2008
SOURCE
Pharmaceutical Medicine - New Zealand;2008, Vol. 22 Issue 6, p341
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
The author recalls various issues related to drug safety in the U.S. which transpired in 2008. The Food and Drug Administration (FDA) has received a 9% increase in funding at $1.73 billion, 39% and 13.5% of which went to the Centers for Drug and Biologics Evaluation and Research (CDER and CBER), respectively. He cites the significance of the approval of the Avastin bevacizumab from Genentech for first line treatment of metastatic HER-2 negative breast cancer. The provisions of the FDA Amendments Act (FDAAA) implemented on March 25 are mentioned.
ACCESSION #
35990176

 

Related Articles

  • Avastin Gets More Time for Review.  // Pharmaceutical Representative;Oct2010, Vol. 40 Issue 10, p10 

    The article accounts on the report issued by the U.S. Food and Drug Administration regarding the extension of the review period for Avastin, a drug used to treat cancer including cancer of the breast, lungs, colon, brain, and kidneys.

  • Medicare to cover expensive cancer treatments.  // PharmacoEconomics & Outcomes News;7/16/2011, Issue 633, p11 

    The article reports on the plan of Medicare to cover Avastin bevacizumab for breast cancer treatment regardless of the decision of the U.S. Food and Drug Administration (FDA) to rescind Avastin approval for such indication in July 2011.

  • Most Doctors Back Avastin Withdrawal.  // Chain Drug Review;2/28/2011, Vol. 33 Issue 4, p93 

    The article reports on the support of fifty-eight percent of physicians in a poll by Sermo, on the move of the Food and Drug Administration (FDA) to pull the breast cancer indication for Avastin from the market.

  • REMS -- One Year Later. Baker, Danial D. // Hospital Pharmacy;May2010, Vol. 45 Issue 5, p348 

    The author discusses the Risk Evaluation and Mitigation Strategy (REMS) program he initiated in 2009. He traces the development of the scheme which carried an amendment to the U.S. Food and Drug Administration (FDA) Act in 2007 and gave the legal foundation for the advancement of an...

  • FDA says GOP amendment could gut food-safety effort. Pecquet, Julian // Hill;6/8/2011, Vol. 18 Issue 80, p14 

    The article reports on the anticipation of the U.S. Food and Drug Administration (FDA) that a Republican-sponsored amendment to FDA budget may limit the power of the agency on public health protection.

  • Advisory Panel Rejects Avastin for Breast Cancer Treatment. Koroneos, George // Pharmaceutical Executive;Aug2010, Vol. 30 Issue 8, p13 

    The article reports on the decision of the U.S. Food and Drug Administration to discontinue the use of Avastin or bevacizumab as a treatment for breast cancer due to reports on inefficacy.

  • FDA extends review period of bevacizumab for treatment of advanced HER-2-negative breast cancer.  // Hem/Onc Today;10/10/2010, Vol. 11 Issue 19, p22 

    This article reports on the extension by the U.S. Food and Drug Administration (FDA) of the review period for the supplemental biologics license applications of bevacizumab for the treatment of previously untreated advanced HER-2-negative breast cancer.

  • FDA Panel Votes Against Avastin Use For Breast Cancer Patients. Young, Donna // BioWorld Today;12/6/2007, Vol. 18 Issue 236, p1 

    The article deals with the pending approval by the U.S. Food and Drug Administration (FDA) of Genentech's Avastin in combination with the chemotherapy agent paclitaxel as a treatment for metastatic breast cancer. Richard Pazdur of the FDA said that the agency would consider the overall...

  • Bevacizumab in Metastatic Breast Cancer: Ready for Prime Time? Mandock, Katherine; Soefje, Scott A.; Adams, R. // Journal of Hematology Oncology Pharmacy;Dec2011, Vol. 1 Issue 4, p6 

    The article focuses on the U.S. Food and Drug Administration's (FDA) decision to remove bevacizumab's current labeled indication for metastatic breast cancer (MBC). Postapproval trials required with the FDA approval for bevacizumab for treatment did not demonstrate an overall survival (OS)...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics